Skip to content

Study · Non-randomized trial · n = 173 · 1994

4 results

Nafarelin therapy in endometriosis: long-term effects on bone mineral density.

Orwoll ES, Yuzpe AA, Burry KA, Heinrichs L, Buttram VC Jr, Hornstein MD

American journal of obstetrics and gynecology1 Nov 1994Cited by 21 (Europe PMC)

PMID7977523 (opens in a new tab)DOI10.1016/0002-9378(94)90136-8 (opens in a new tab)PepBankPUB-07977523
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In women with endometriosis, spinal bone mineral density declined similarly within both the 3- and 6-month nafarelin groups.

    In plain wordsIn women with endometriosis, spinal bone density declined similarly in both nafarelin duration groups.

    Peptide
    Nafarelin
    Outcome
    DecreaseSpinal bone mineral density
    Study

    n = 173

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 micrograms twice a day · intranasal · 3 or 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral density declined at spinal and femoral sites similarly in both 3- and 6-month treatment groups.
    2 context sentences
    Summary · context
    Women with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms intranasally twice a day) for either 3 or 6 months in a double-blind fashion.
    Summary · context
    Bone mineral density was measured by dual energy x-ray absorptiometry at lumbar spine and proximal femoral sites for 18 months.
  2. 02HumanNon-randomized trialSafety outcome

    In women with endometriosis, femoral bone mineral density declined similarly within both the 3- and 6-month nafarelin groups.

    In plain wordsIn women with endometriosis, thigh bone density declined similarly in both nafarelin duration groups.

    Peptide
    Nafarelin
    Outcome
    DecreaseFemoral bone mineral density
    Study

    n = 173

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 micrograms twice a day · intranasal · 3 or 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mineral density declined at spinal and femoral sites similarly in both 3- and 6-month treatment groups.
    2 context sentences
    Summary · context
    Women with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms intranasally twice a day) for either 3 or 6 months in a double-blind fashion.
    Summary · context
    Bone mineral density was measured by dual energy x-ray absorptiometry at lumbar spine and proximal femoral sites for 18 months.
  3. 03HumanNon-randomized trialSafety outcome

    In women with endometriosis, bone density partially but incompletely returned toward baseline after 12 to 15 months of follow-up after nafarelin.

    In plain wordsIn women with endometriosis, bone density partly recovered after nafarelin but did not return fully to baseline.

    Peptide
    Nafarelin
    Outcome
    IncreaseBone mineral density recovery
    Study

    n = 173

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 micrograms twice a day · intranasal · 3 or 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a partial, but incomplete, return to baseline levels after 12 to 15 months of follow-up.
    2 context sentences
    Summary · context
    Women with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms intranasally twice a day) for either 3 or 6 months in a double-blind fashion.
    Summary · context
    Bone mineral density was measured by dual energy x-ray absorptiometry at lumbar spine and proximal femoral sites for 18 months.
  4. 04HumanObservational studySafety outcome

    In women treated with nafarelin for endometriosis, higher dietary calcium intake was linked to more complete bone mass recovery.

    In plain wordsIn women treated with nafarelin for endometriosis, higher calcium intake was linked to more complete bone recovery.

    Peptide
    Nafarelin
    Outcome
    IncreaseBone mass recovery by calcium intake
    Study

    n: not reported in source

    Comparator
    Lower dietary calcium intake
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 micrograms twice a day · intranasal · 3 or 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The recovery of bone mass was more complete in subjects with higher dietary calcium intakes.
    2 context sentences
    Summary · context
    Women with established endometriosis (N = 173) were randomized to receive nafarelin (200 micrograms intranasally twice a day) for either 3 or 6 months in a double-blind fashion.
    Summary · context
    Bone mineral density was measured by dual energy x-ray absorptiometry at lumbar spine and proximal femoral sites for 18 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.